{"id":192378,"date":"2025-09-30T13:41:08","date_gmt":"2025-09-30T13:41:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/192378\/"},"modified":"2025-09-30T13:41:08","modified_gmt":"2025-09-30T13:41:08","slug":"symbiosis-completes-qualification-of-new-fdp-50-flexicon-automated-fill-finish-line","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/192378\/","title":{"rendered":"Symbiosis Completes Qualification of New FDP 50 Flexicon Automated Fill\/Finish Line\u00a0"},"content":{"rendered":"<p><a href=\"https:\/\/www.contractpharma.com\/company-profile\/symbiosis-pharma\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Symbiosis Pharmaceutical Services<\/a>, a global contract manufacturing organization (CMO) specializing in the sterile manufacture of injectable drug products, has successfully completed qualification of its new FPD 50 Flexicon automated fill\/finish line at its new commercial production facility in Stirling, Scotland.\u00a0<\/p>\n<p>The fully integrated sterile liquid fill\/finish system operates under a Grade A Restricted Access Barrier System (RABS). Designed to deliver with both precision and efficiency, it incorporates rapid transfer ports for aseptic handling and high-accuracy vial filling with flexicon pump technology. The system also features a rotary crimp mechanism to ensure consistent overseal application and secure closure.\u00a0<\/p>\n<p>Colin MacKay, CEO of Symbiosis, said: \u201cThe qualification of our automated fill\/finish line is a major step forward for Symbiosis. It enhances our technical capabilities and expands our capacity at a time when demand for high-quality sterile manufacturing continues to grow. Most importantly, it strengthens our ability to help clients bring vital therapies to patients quickly and to the highest regulatory standards.\u201d\u00a0<\/p>\n<p>Symbiosis will commence commercial production at their new facility in Q4 2025, manufacturing batches of up to 15,000 vials, and representing the latest in a series of recent milestones for the company.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Symbiosis Pharmaceutical Services, a global contract manufacturing organization (CMO) specializing in the sterile manufacture of injectable drug products,&hellip;\n","protected":false},"author":2,"featured_media":192379,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4,450,451,3,452,453],"class_list":["post-192378","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-breaking-news","tag-breakingnews","tag-headlines","tag-news","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/192378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=192378"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/192378\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/192379"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=192378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=192378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=192378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}